? CANCER RESEARCH TRAINING AND EDUCATION COORDINATION The Center for Cancer Mentoring, Education, Leadership, and Oncology-related Training (CAMELOT) serves as the centralized hub for the Ohio State University Comprehensive Cancer Center (OSUCCC) fostering cancer research and education, and disseminating those opportunities. CAMELOT?s efforts begin at the high school level, continue through undergraduate and graduate training, and then extend through post-doctoral training and into early faculty development and mentoring. CAMELOT is directed by Dr. Lawrence Kirschner, the OSUCCC Associate Director of Training and Education. He is assisted by Drs. Deepa Sampath, Elizabeth Klein, and Rosa Lapalombella. CAMELOT coordinates training and education programs through: 1) direct programs (e.g., for high school, Pelotonia fellows, external undergraduate student summer rotations including students from Ohio Historically Black Universities and Colleges); 2) integrating College of Medicine (COM) programs with OSUCCC activities and opening them to trainees and junior faculty outside the COM; 3) supporting grant submissions by junior faculty; and 4) supporting training grant submissions. The Pelotonia Fellowship Program (PFP), a major commitment by the OSUCCC to fellowship training, has been in existence for 10 years, and provides stipends and research support to fellows from the undergraduate to the postdoctoral fellowship level. OSUCCC provides $2-3M/year to support the PFP. During the current grant cycle, 251 pre- and postdoctoral fellowships awarded, of which 155 had mentors who were OSUCCC members from all five of the OSUCCC research programs and 10 of the 15 OSU Colleges. More than 90% of these trainees are currently active as cancer researchers. New programs developed by CAMELOT include two cancer research-focused pipeline programs, one for local underrepresented minority high school students and another for current OSU undergraduates.
The Specific Aims are to: 1) provide integration and coordination of training opportunities for cancer research across the OSUCCC and university ecosystem, and region, including high schools and colleges; 2) enhance formalized programming for cancer-based mentoring including both peer-to-peer and senior-to-junior mentoring; and, 3) develop an integrated system to enable assessment and outcome tracking for trainees at all levels of engagement with the OSUCCC (grants, papers, academic positions, etc.) to foster continuous quality improvement in educational and career development activities. The OSUCCC is planning robust faculty recruitment around strategic research priorities that will create new opportunities for education and training. To accommodate this, a bigger pipeline for training is planned in the next funding cycle. The OSUCCC will: 1) expand graduate and postgraduate training slots and programs for high school students; 2) establish the Young Cancer Investigator Faculty Academy that focuses on OSUCCC wet-lab researchers to support development of independent research programs; 3) establish a uniform tracking system for trainees; and 4) foster submissions of R25 and T32 training grants, including supplements.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Zhang, Tianyu; Xu, Jielin; Deng, Siyuan et al. (2018) Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data. PLoS One 13:e0196351
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
LaPak, Kyle M; Vroom, Dennis C; Garg, Ayush A et al. (2018) Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget 9:25386-25401
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Kaffenberger, Benjamin H; Hinton, Alice; Krishna, Somashekar G (2018) The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol 79:659-663.e2
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Rahnemai-Azar, Amir A; Cloyd, Jordan M; Weber, Sharon M et al. (2018) Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency. J Clin Transl Hepatol 6:97-104
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Kodigepalli, Karthik M; Bonifati, Serena; Tirumuru, Nagaraja et al. (2018) SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle 17:1124-1137
Wang, Zhilian; Li, Zaibo; Li, Jing et al. (2018) Prevalence and Distribution of HPV Genotypes in 1387 Women with Cervical Intraepithelial Neoplasia 2/3 in Shanxi Province, China. J Cancer 9:2802-2806

Showing the most recent 10 out of 2602 publications